8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition

The adenosine analog 8-chloroadenosine has been shown to deplete ATP and inhibit tumor growth in hematological malignancies as well as in lung and breast cancer cell lines. We investigated effects of 8-chloroadenosine on clear cell (cc) renal cell carcinoma (RCC) cell lines. 8-chloroadenosine was effective against ccRCC cell viability in vitro, with IC50 ranging from 2 μM in the most sensitive CAKI-1 to 36 μM in the most resistant RXF-393. Proteomic analysis by reverse-phase protein array revealed that 8-chloroadenosine treatment leads to inhibition of the mTOR pathway. In time-course experiments, 8-chloroadenosine treatment rapidly activated AMPK, measured by AMPK and ACC phosphorylation, and subsequently caused dephosphorylation of p70S6K and ribosomal protein RPS6 in the sensitive cell lines. However, in the resistant cell lines, AMPK activity and the mTOR pathway were unaffected by the treatment. We also noted that the resistant cell lines had elevated basal levels of phospho RPS6 and AKT. Inhibition of PI3K pathway enhanced the efficacy of 8-chloroadenosine across all cell lines. Our observations indicate that 8-chloroadenosine activity is associated with inhibition of the mTOR pathway, and that phospho RPS6 and PI3K pathway activation status may determine resistance. Among solid tumors, RCC is one of the few susceptible to mTOR inhibition. We thus infer that 8-chloroadenosine may be effective in RCC by activating AMPK and inhibiting the mTOR pathway.

[1]  T. Choueiri,et al.  First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2014, Clinical genitourinary cancer.

[2]  C. M. Stellrecht,et al.  ATP directed agent, 8-chloro-adenosine, induces AMP activated protein kinase activity, leading to autophagic cell death in breast cancer cells , 2014, Journal of Hematology & Oncology.

[3]  T. Tsakiridis,et al.  AMP-activated protein kinase (AMPK) beyond metabolism , 2014, Cancer biology & therapy.

[4]  F. Ross,et al.  Phosphorylation by Akt within the ST loop of AMPK-α1 down-regulates its activation in tumour cells , 2014, The Biochemical journal.

[5]  M. Bonini,et al.  The multifaceted activities of AMPK in tumor progression—why the “one size fits all” definition does not fit at all? , 2013, IUBMB life.

[6]  Yu-xiang Zhang,et al.  E2F1-mediated DNA damage is implicated in 8-Cl-adenosine-induced chromosome missegregation and apoptosis in human lung cancer H1299 cells , 2013, Molecular and Cellular Biochemistry.

[7]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[8]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[9]  G. Mills,et al.  AMPK: a contextual oncogene or tumor suppressor? , 2013, Cancer research.

[10]  X. Bai,et al.  Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. , 2013, Urologic oncology.

[11]  Qiang Zhang,et al.  A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  Navdeep S. Chandel,et al.  AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress , 2012, Nature.

[13]  R. Shaw,et al.  The AMPK signalling pathway coordinates cell growth, autophagy and metabolism , 2011, Nature Cell Biology.

[14]  B. Kemp,et al.  AMPK Is a Direct Adenylate Charge-Regulated Protein Kinase , 2011, Science.

[15]  B. Viollet,et al.  AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 , 2011, Nature Cell Biology.

[16]  R. Gartenhaus,et al.  AMPK signaling: A targetable tumor suppressor pathway? , 2010, Cancer biology & therapy.

[17]  B. Viollet,et al.  AMPK as a therapeutic target in renal cell carcinoma , 2010, Cancer biology & therapy.

[18]  K. Coombes,et al.  Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  C. M. Stellrecht,et al.  A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels , 2010, Breast Cancer Research and Treatment.

[20]  Jennifer B Dennison,et al.  Preclinical activity of 8‐chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis , 2009, British journal of haematology.

[21]  Shuxing Zhang,et al.  Inhibition of ATP synthase by chlorinated adenosine analogue. , 2009, Biochemical pharmacology.

[22]  H. Jia,et al.  Induction of p14ARF by E2F1 Contributes to 8-Chloro-Adenosine-Induced Apoptosis in Human Lung Cancer H1299 Cells , 2009, Chemotherapy.

[23]  W. Kaelin,et al.  Kinase requirements in human cells: III. Altered kinase requirements in VHL−/− cancer cells detected in a pilot synthetic lethal screen , 2008, Proceedings of the National Academy of Sciences.

[24]  C. Stratakis,et al.  Protein kinase A-independent inhibition of proliferation and induction of apoptosis in human thyroid cancer cells by 8-Cl-adenosine. , 2008, The Journal of clinical endocrinology and metabolism.

[25]  C. M. Stellrecht,et al.  Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. , 2007, Cancer research.

[26]  H. Jia,et al.  8-Chloro-adenosine inhibits growth at least partly by interfering with actin polymerization in cultured human lung cancer cells. , 2006, Biochemical pharmacology.

[27]  F. Tödtling,et al.  One size fits all?: Towards a differentiated regional innovation policy approach , 2005 .

[28]  M. Keating,et al.  Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. , 2005, Blood.

[29]  D. Zheng,et al.  8-Chloro-adenosine sensitizes a human hepatoma cell line to TRAIL-induced apoptosis by caspase-dependent and -independent pathways. , 2004, Oncology reports.

[30]  C. M. Stellrecht,et al.  RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. , 2003, Cancer research.

[31]  V. Gandhi,et al.  Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats , 2002, Cancer Chemotherapy and Pharmacology.

[32]  V. Gandhi,et al.  8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. , 2001, Cancer research.

[33]  D. Hardie,et al.  5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? , 1995, European journal of biochemistry.

[34]  L. Zhang,et al.  [Antitumor activities of 8-chloroadenosine in vivo and in vitro]. , 1995, Zhonghua zhong liu za zhi [Chinese journal of oncology].